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Background: The aim of this study is to compare metabolic parameters, malondialdehyde as a lipid oxidation marker,
and lipid profiles between dogs with untreated hyperlipidemia and hyperlipidemia with treatment, in order to examine
the usefulness of malondialdehyde and lipid profiles as diagnostic parameters at early stages of hyperlipidemia.
Results: Dog samples were collected from four different veterinary clinics across Japan from March to June 2013. They
were separated into three groups: control, untreated hyperlipidemia based on temporally screening, and hyperlipidemia
with current anti-hyperlipidemic (statins and fibrates) treatment. Triglyceride levels of untreated hyperlipidemia dogs were
significantly higher than those of control dogs. ALT levels of hyperlipidemic dogs with treatment were the highest among
three groups. VLDL and LDL of both cholesterol and triglyceride of untreated hyperlipidemia dogs were the highest
among three groups. HDL1 levels in triglyceride of hyperlipidemia dogs with treatment were significantly higher than
those of control and untreated hyperlipidemia dog. Malondialdehyde concentrations of untreated hyperlipidemia dogs
were significantly higher than those of control and hyperlipidemic dogs with treatment.
Conclusions: In this study, dogs with untreated hyperlipidemia clearly showed abnormal lipid status, whereas
hyperlipidemic dogs under anti-hyperlipidemia treatment showed more normal lipid status suggesting the effectiveness
of the therapy. Anti-hyperlipidemics (statins and fibrates) for dogs are also effective in relieving elevated levels of lipids
and lipid oxidation. Plasma lipid (triglyceride and cholesterol) profiles and malondialdehyde are useful diagnostic tools for
identifying early stages of untreatment hyperlipidemia in dogs.
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Aberrations in plasma cholesterol and triglyceride levels
are indicative of diseases associated with obesity and dia-
betes mellitus [1]. Mounting evidences have suggested the
increasing recognition of clinical importance of hyperlip-
idemia in dogs. Hyperlipidemia causes other disorders
such as pancreatitis, hypotiroidism [2,3]. However, many
of hyperlipidemia dogs physically appear healthy and do
not usually exhibit any symptoms. Therefore, many veter-
inary practitioners and dog owners exhibit little interest in
unsymptomatic lipid metabolism abnormality. Only when
the disease progresses and the dog become severely hyper-
lipidemic, they initiate therapy with anti-hyperlipidemic* Correspondence: d0908@nvlu.ac.jp
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unless otherwise stated.drugs. In 2012, we set the new screening criteria for de-
tecting early stages of hyperlipidemia in dogs [4]. When
we evaluated apparently healthy dogs using these criteria,
23.7% dogs (9 of healthy 38 dogs) were diagnosed with
hyperlipidemia. We think that the use of hyperlipidemia
screening is valuable in early diagnosis, which in turn, al-
lows for an implementation of early interventions such as
diet change, exercise, and more frequent veterinary check-
ups. In humans, plasma lipid profile analysis can be useful
in diagnosing lipid metabolic disorders. Lipoproteins are
believed to play important roles in energy and lipid metab-
olism of animals, and can reflect metabolic changes. Alter-
ations in the dog’s lipoprotein cholesterol fractions are
possibility of aberrations of lipid metabolism due to hyper-
lipidemia and/or obesity as in human [5].
Hyperlipidemia also induces oxidative stress, and mal-
ondialdehyde (MDA) is one of the end products in lipidhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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animals with obesity and diabetes mellitus and increased
MDA indicated elevations of lipid oxidation in tissues [6].
Humans with apparent increase in Malondialdehyde-
Modified LDL were shown to be more predisposed to de-
veloping arterosclerosis. However it should be noted, dog’s
lipoprotein density profiles and lipid metabolism are dif-
ferent from those of humans [5,7].
The aim of this study is twofold. First is to reveal how
the effect of the anti-hyper lipidemic therapy on lipid pro-
files of hyperlipidemia dogs. There are 2 types of hyperli-
pedemia dogs; Fisrt hyperlipidemia dog group is classified
as untreated hyperlipedemia, and another group of hyper-
lipidemia dogs managed with lipid-lowering drugs was
classified as hyperlipidemia with current treatment.
Second is to compare metabolic parameters, MDA as a
lipid oxidation marker, and lipid profiles between dogs with
untreated hyperlipidemia, and hyperlipidemia with treatment
in order to examine the usefulness of MDA and lipid profiles
as diagnostic parameters at early stages of hyperlipidemia.
Methods
Animals
21 dog samples were collected from four different veterinary
clinics across Japan (Ibaraki, Kanagawa) from March to June
2013. The test subjects included 4 Miniature Dachshunds, 3
Toy Poodles, 2 Golden Retrievers, and 2 Shih Tzus and so
on. Breeds generally known to exhibit hyperlipidemia such
as Miniature Schunauzers and Shetland Sheepdogs [8,9]
were excluded from our subjects. 13 dogs (age: median
8.0 years old; number of females (F): 8; number of males
(M): 5; body weight: median 5.6 kg) were classified as
healthy control subjects by each clinical veterinarian. 4 dogs
(age: median 12.5 years; M: 4; body weight: median 8.9 kg)
under anti-hyperlipidemic therapy (statins and fibrates) were
diagnosed as severely hyperlipidemic. The remaining 4 dogs
(age: median 9.5 years; F: 3; M: 1; body weight: median
7.7 kg) were diagnosed as hypelipidemic based on the
screening of hyperlipidemia as follow [4]. A subject may be
classified as hyperlipedemic if the biochemical analysis of
the plasma shows any two of the following 3 factors:
1) Elevated triglyceride level >165 mg/dL
2) Elevated total cholesterol level >200 mg/dL
3) Elevated free fatty acids level >1.5 mEq/L
All dog owners gave us written informed consent be-
fore enrolment in this study. This study was approved
by the Nippon Veterinary and Life Science University
Animal Research Committee.
Blood sampling and plasma metabolite analysis
Postprandial blood samples were collected from the fore-
limb vein into heparinized plastic tubes, and plasma wasrecovered via centrifugation at 4°C and stored at −25°C
until further use. Plasma glucose, triglycerides (TG), total
cholesterol (T-cho), total protein, aspartate aminotransfer-
ase, and alanine aminotransferase (ALT), alkaline phosphat-
ase (ALP), albumin, albumin verses globulin ratio, total
bilirubin, total bile acids, γ-GTP were measured by auto-
analyzer (Monolis, Inc, Tokyo, Japan) using the manufac-
turer’s reagents. NEFA, adiponectin, insulin and MDA were
determined with NEFA-C test Wako (Wako Pure Chemical
Industries, Inc., Tokyo), Dog adiponectin ELISA kit (Circulex
Co., Ltd, Nagano), and Lbis dog Insulin kit (Shibayagi
Co., Gunma), Malondialdehyde Assay kit, (Northwest Life
Science Specialties LLC, Vancouver, WA) respectively.
In order to examine lipoprotein fractions of cholesterol
and triglyceride for all dogs, we performed biphasic agar-
ose gel electrophoresis method using commercial Quick-
gel Lipo gels (Helena Laboratories, Saitama). Lipoproteins
were separated by electrophoretic technique and analyzed
using a Helena Laboratories Epalyzer 2 Electrophoresis
processing Analyzer. Lipoprotein fractions were assessed
and analyzed using Edbank III analysis software (Helena
Laboratories, Saitama, Japan). Lipoprotein electrophoresis
pattern consisted of 4 bands. The bands from left to right
were: α1-migrating lipoproteins (HDL2 and HDL3), α2-
migrating lipoproteins (HDL1), β-migrating lipoproteins
(LDL and VLDL), and κ band (small% of chylomicrons)
remaining at the origin (Mori et al., [5]).
Statistical analysis
Values were expressed in medians with inter-quartile range
(25th Percentile and 75th Percentile). Statistical significance
was determined by One-way Ananysis of Variance by Ranks
among groups. All tests were performed using Sigmaplot
version.11.2 (Systat Software Inc., San Diego, CA, USA).
The significance level was set at P < 0.05.
Results
As shown in Table 1, triglycerides level of untreated hyper-
lipidemia group was significantly higher than those of con-
trol group. ALT level of hyperlipidemia with treatment
group was the highest among three groups. ALP level of
hyperlipidemia dog with treatment was significantly higher
than those of control and untreated hyperlipidemia dogs.
Although no significant difference in total cholesterol con-
centration was observed, total cholesterol level of hyperlip-
idemic dogs with treatment tended to be higher compared
to the other groups. VLDL and LDL in cholesterol and tri-
glyceride of untreated hyperlipidemia dogs were the highest
among three groups. HDL1 level in triglyceride of hyperlip-
idemia with treatment group was significantly higher than
those of control and untreated hyperlipidemic groups.
Chylomicron level in triglyceride of untreated hyperlipid-
emia dogs was higher than those of control and hyperlipid-
emic dogs with treatment. As shown in Figure 1. MDA
Table 1 Comparison of plasma biomarker levels and lipoprotein profiles among control, hyperlipidemia dogs
with/without treatment
Group (n) Control (13) Hyperlipidemia
Untreatment (4) With treatment (4)
Age 8.0 (2.8-9.3) 9.5 (6.0-11.5) 12.5 (12.-15.0)
Body condition score 3.0 (3.0-4.0) 3.5 (2.3-4.8) 3.0 (3.0-4.0)
Body weight (kg) 5.6 (4.3-14.5) 7.7 (3.0-21.3) 8.9 (5.6-26.9)
Total choresterol (mg/dL) 240 (170–351) 241 (231–358) 367 (347–390)
Triglycerid (mg/dL) 48 (28–163) 252 (196–311)* 81 (61–88)
Total protein (g/dL) 6.8 (6.4-7.4) 7.5 (6.7-8.0) 7.3 (7.1-7.7)
Albmin (g/dL) 3.3 (3.0-3.4) 3.4 (3.0-3.8) 3.3 (3.0-3.6)
Albumin/globulin ratio 0.88 (0.79-0.97) 0.83 (0.80-0.89) 0.78 (0.76-0.88)
Total bilirubin (mg/dL) 0.1 (0.1-0.2) 0.2 (0.1-0.2) 0.1 (0.1-0.2)
AST (IU/L) 33 (24–39) 35 (20–38) 33 (26–45)
ALT (IU/L) 44 (37–67) 40 (24–65)** 123 (75–315)*
ALP (IU/L) 127 (72–218) 335 (101–2259) 877 (318–1113)*
γ-GTP (IU/L) 6.1 (3.9-7.7) 5.1 (2.8-7.7) 7.7 (6.0-35.8)
Total bile acid (mg/dL) 5.7 (2.5-23.5) 15.8 (6.4-104.3) 10.4 (6.2-31.2)
Glucose (mg/dL) 90 (81–110) 102 (96–109) 103 (90–375)
NEFA (mEq/L) 0.78 (0.64-0.97) 0.73 (0.55-1.14) 0.52 (0.41-0.65)
Insulin (ng/mL) 1.1 (0.8-1.7) 0.7 (0.6-1.1) 2.4 (1.2-2.5)
Adiponectin (μg/mL) 18.4 (15.9-30.1) 31.9 (17.1-38.9) 23.8 (19.0-25.9)
Cholesterol profiles
HDL2,3 (mg/dl) 191.8 (143.1-225.0) 191.2 (167.2-240.0) 229.7 (215.8-242.8)
HDL1 (mg/dl) 31.1 (24.3-85.5) 41.7 (25.2-124.4) 119.9 (96.3-136.6)
VLDL/LDL (mg/dl) 5.8 (3.3-14.4) 22.5 (16.5-35.7)* 21.5 (7.7-35.9)
CM (mg/dl) 0.0 (0.0-0.2) 1.5 (0.0-6.7) 0.0 (0.0-0.0)
Triglyceride profiles
HDL2,3 (mg/dl) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.2)
HDL1 (mg/dl) 0.5 (0.0-1.8) 0.9 (0.75-5.0) 3.0 (1.9-6.5)*
VLDL/LDL (mg/dl) 47.5 (28.1-108.4) 193.1 (119.0-264.5)*,** 67.9 (59.7-72.3)
CM (mg/dl) 0.5 (0.0-48.7) 58.6 (0.0-119.3) 5.6 (0.0-14.5)
Values are presented as median. Numbers in parentheses present from 25% to 75% value.
*Significantly different (p < 0.05) from the values of Control group by Kruskal-Wallis One Way Analysis of Variance on Ranks.
**Significantly different (p < 0.05) from the values of hyperlipidemia with treatment group by Kruskal-Wallis One Way Analysis of Variance on Ranks.
All dogs were also determined by palpation and inspection on with a body condition score (BCS: a 5 point scale) the five-point scale: (1) very thin, (2)
underweight, (3) ideal, (4) overweight, and (5) obese.
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highest among three groups.
Discussion
Various diagnostic criteria for hyperlipidemia have al-
ready been established. The first states plasma total
cholesterol level of over 300 mg/dl as a criterion [8], and
another sets both plasma triglyceride and plasma choles-
terol levels to be over 500 mg/dl [3]. The above methods
only detect dogs which are in severe hyperlipidemic
condition and in need of clinical interventions. Ourscreening methods aim to detect early stages of hyperlip-
idemia in dogs that may be missed by veterinarinary
practitioners. In current study, abnormal lipid satus in
plasma was clearly detected in untreated hyperlipidemia
group. In this study, most of the hyperlipidemic dogs
were under anti-hyperlipidemic therapy as recom-
mended by their veterinarians. The therapy appeared to
be fully effective since triglyceride level in hyperlipid-
emia with treatment group was lower than those of
untreated hyperlipidemia group and there was no signifi-


































Figure 1 Change of MDA concentrations among control,
hyperlipidemia dogs with/without treatment. Graph is expressed
as median with inter-quartile range (25th Percentile and 75th
Percentile). * Significantly different (p < 0.05) from the values of
Control group by Kruskal-Wallis One Way Analysis of Variance on
Ranks. ** Significantly different (p < 0.05) from the values of
hyperlipidemia with treatment group by Kruskal-Wallis One Way
Analysis of Variance on Ranks.
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hyperlipidemic dogs were on fibrates and one dog was
on statins. The fibrates are considered the most effective
hypertriglyceridemia drugs [10] and the statins are a
class of LDL-cholesterol lowering drugs [11,12]. ALT
levels in hyperlipidemic dogs with treatment were ex-
pected to be elevated due to hepatic metabolism of these
drugs. HDL1 is a large floating particle which plays an
important role in reverse cholesterol transport. LDL
functions similarly as HDL 1, and is unique to dogs [5].
HDL1 fractions of both cholesterol and triglycerides in
hyperlipidemia with treatment group were the highest
among three groups. Additionally, we confirmed correla-
tions between MDA and lipid profiles for each group.
MDA level of normal group showed strongly positive
correlations with triglycerides level, VLDL of triglycer-
ides (TG r = 0.89, VLDL of TG r = 0.82). Remarkably,
MDA level of untreated hyperlipidemia group showed
strongly positive correlations with a lot of lipid profiles
(T-Cho r = 0.83, HDL2 and HDL3 of T-cho r = 0.86,
HDL1 of T-cho r = 0.72, VLDL and LDL of T-cho r =
0.97, HDL1 of TG r = 0.78, VLDL and LDL of TG r =
0.79). Adversely MDA of hyperlipidemia with treatment
correlated negatively with total cholesterol level (T-cho,
r = −0.75). The highest value of coefficient of correla-
tion was seen between MDA and VLDL/LDL of total
cholesterol.
Anti-hyperlipidemic drugs were also effective in redu-
cing lipid oxidation. MDA concentration in untreated
hyperlipidemic dogs was the highest among three groups.MDA is an end product of lipid peroxidation, and MDA-
modified LDL (MDA-LDL) is generated via lipid peroxida-
tion or during platelet aggregation. Both statins and
fibrates therapies had a positive effect on reducing serum
MDA-LDL concentrations in human lipid metabolic
mechanism [13,14]. Also statins and fibrates in dogs are
effective in relieving the increased lipids and lipid oxida-
tion. Untreated hyperlipidemia group showed significantly
higher plasma triglycerides concentration than control
and hyperlipidemia with treatment groups. Associated
VLDL and LDL in lipoprotein fractions were also higher
than those of control and hyperlipidemia with treatment
groups. As untreated hyperlipidemia dogs showed abnor-
mality in lipid metabolism, our new criteria in hyperlipid-
emia is shown to be beneficial in metabolic disease
prevention. Xenoulis et al. [15] also reported in current
paper that lipoprotein profiles in dogs could potentially be
useful as diagnostic tools in idenfication of dogs suspected
of having lipoprotein abnormalities.
Unfortunately, in this study, there was an insufficient
number of with/ without treatment hyperlipidemic dogs.
The small number of dogs may result in low statistical
power, hence results and conclusions need to be inter-
preted with care. However, this study showed that changes
in lipid metabolism are reflected in liver. In the future, we
hope to add more sample numbers and to repeat our
study using different stages of hyperlipidemia dogs and es-
tablish base values of lipid profiles and MDA concentra-
tions as new markers in hypelipidemia screening in order
to validate our results.
Conclusions
In this study, dogs with untreated hyperlipidemia clearly
showed abnormal lipid status, whereas hyperlipidemic
dogs under anti-hyperlipidemia treatment showed more
normal lipid status suggesting the effectiveness of the
therapy. Plasma lipid (triglycerides and cholesterol) pro-
files and MDA may be useful as diagnostic tools for
early stages of hyperlipidemia dogs.
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